COSCIENS Biopharma Inc.
CSCIF Healthcare Biotechnology
COSCIENS Biopharma Inc.’s revenue for fiscal 2025 (year ended December 2025) was $7.5 million, down 21.8% from fiscal 2024. In the quarter to June 2026, revenue grew 30.0%, EPS grew 92.6% and free cash flow grew 113.3%, each against the same quarter a year earlier.
Follow CSCIF
COSCIENS Biopharma Inc. (CSCIF) EV/Sales
As of 16 October 2026, COSCIENS Biopharma Inc. (CSCIF) trades at a EV/Sales of 0.2×. Over the past ten years it has ranged from −77.8× (November 2015) to 8.1× (April 2019); the current reading is higher than 92% of that period. That is below the Biotechnology industry median of 9.2× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | −0.7× | — |
| FY2024 | −1.5× | — |
| FY2023 | −0.3× | — |
| FY2022 | −8.0× | — |
| FY2021 | −9.8× | — |
| FY2020 | −5.0× | — |
| FY2019 | −4.8× | — |
| FY2018 | 0.1× | (98.64%) |
| FY2017 | 4.4× | — |
| FY2016 | −10.9× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | −0.3× | — |
| Mar 2026 | −0.5× | — |
| Dec 2025 | −0.7× | — |
| Sep 2025 | −0.7× | — |
| 42 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| IMRN IMMURON compare | −3.5× |
| JAGX Jaguar Animal Health, Inc. compare | −0.1× |
| QNRX Quoin Pharmaceuticals, Ltd. Sponsored ADR compare | n/m |
| MTVA MetaVia Inc. compare | n/m |
| ADIL Adial Pharmaceuticals, Inc. compare | n/m |
| NKGN NKGen Biotech, Inc. compare | n/m |
| CSCIF COSCIENS Biopharma Inc. | 0.2× |
| SNTI Senti Biosciences, Inc. compare | 0.3× |
| BOLT Bolt Biotherapeutics, Inc. compare | 1.6× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)